Spire I & II

This Study Evaluated The Pcsk9 Inhibitor, Bococizumab (PF04950615;RN316), Compared To Placebo, In Reducing The Occurrence Of Major Cardiovascular Events:

  • Cardiovascular Death
  • Myocardial Infarction
  • Stroke
  • Unstable Angina Requiring Urgent Revascularization

Study Metrics

Sites Initiated

50

Sites Randomized

45

Patients Screened

860

Patients Randomized

338